Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-CMV therapy - Kemin Pharma

Drug Profile

Research programme: anti-CMV therapy - Kemin Pharma

Alternative Names: KPE00001015; KPE00001116; KPE1015; KPE1116

Latest Information Update: 23 Sep 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kemin Pharma
  • Class Antivirals; Carbohydrates
  • Mechanism of Action Cytomegalovirus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 23 Sep 2008 Discontinued - Preclinical for Cytomegalovirus infections in Belgium (unspecified route)
  • 17 Mar 2008 Preclinical development is ongoing
  • 13 Jan 2005 Lead compounds from this programme are available for licensing worldwide (http://www.kemin.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top